Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Stockholders' Equity

v3.22.1
Consolidated Statements of Stockholders' Equity - USD ($)
shares in Thousands, $ in Thousands
Total
Common Stock
Capital in Excess of Par
Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2020   39,759    
Beginning balance at Dec. 31, 2020 $ 711,002 $ 398 $ 3,222,959 $ (2,512,355)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Net income (loss) (80,407)     (80,407)
Restricted stock (in shares)   13    
Restricted stock 2,609 $ 0 2,609  
Warrant exercises (in shares)   6,385    
Warrant exercises 134,818 $ 64 134,754  
Ending balance (in shares) at Mar. 31, 2021   46,157    
Ending balance at Mar. 31, 2021 768,022 $ 462 3,360,322 (2,592,762)
Beginning balance (in shares) at Dec. 31, 2021   61,371    
Beginning balance at Dec. 31, 2021 1,865,768 $ 614 4,012,358 (2,147,204)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Net income (loss) 39,737     39,737
Restricted stock (in shares)   6    
Restricted stock 2,790   2,790  
Stock Issued During Period, Shares, Acquisitions   117    
Common stock issued for Primexx Acquisition 6,295 $ 1 6,294  
Ending balance (in shares) at Mar. 31, 2022   61,494    
Ending balance at Mar. 31, 2022 $ 1,914,590 $ 615 $ 4,021,442 $ (2,107,467)